A trial to demonstrate that administration of binimetinib treatment using a 45 mg strength tablet is equivalent to 3 tablets of 15 mg.
A trial to demonstrate that administration of binimetinib treatment using a 45 mg strength tablet is equivalent to 3 tablets of 15 mg.
A randomized, single-center, open-label, single dose, two-period, crossover pivotal bioequivalence study comparing binimetinib 3 x 15 mg and 45 mg tablets in healthy participants
Brief summary
Binimitenib (MEKTOVI®) is a marketed drug for the treatment of adults' patients with unresectable or metastatic melanoma presenting a specific mutation (BRAF V600 mutation).
In order to facilitate treatment administration, a new strength tablet containing 45 mg of binimetinib is being developed. As a result, the number of binimetinib tablets to be taken by the patients will be reduced from 6 tablets (6 x 15 mg) to 2 tablets (2 x 45 mg) per day.
The purpose of the trial is to demonstrate the bioequivalence of the two formulations; it means that binimetinib treatment is delivered in the body in the same way (in quantity and speed) with a 45 mg-tablet than with 3 tablets of 15 mg.
Find out where the clinical trial is conducted
Contact Us
Need more information, click on the button to have access to the contact form.
Access to Lay Protocol Synopsis
A summary of the protocol, written in simple terms and describing the objectives of the study, is provided.